Navigation Links
Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
Date:12/19/2007

rket as quickly as possible."

VALSTAR, a sterile solution of valrubicin for intravesical instillation, is the only product approved by the FDA for therapy of bacillus Calmette- Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder. VALSTAR was removed from the market in 2002 due to impurities in the original formulation and was placed on the FDA Drug Shortages List. Indevus acquired VALSTAR through its acquisition of Valera Pharmaceuticals and after completing the resolution of the impurity issue, submitted a chemistry, manufacturing and controls (CMC) NDA supplement to the FDA in May 2007.

About VALSTAR(TM)

VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.

In clinical trials, when provided after transurethral resection, VALSTAR patients had a median 21 months to documented recurrence of disease.

VALSTAR has been shown to induce complete response in only about 1 in 5 patients with BCG-refractory CIS. It is important to note that delaying cystectomy could lead to development of metastatic bladder cancer.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) XR and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of inf
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
7. IsoTis Receives FDA Clearance for Accell Family of Products
8. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
11. XTL Receives Staff Letter From NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... BANGALORE, India , July 1, 2015  Strand ... next generation sequencing technology to empower cancer care, today ... as chief executive officer. In his expanded role as ... all strategy, business expansion and worldwide operations effective immediately.  ... Strand,s chairman and CEO since its founding in 2000, ...
(Date:7/1/2015)... 2015 InferMed , ... will augment ... clinical s olutions suite   Elsevier ... products and services, announced today the acquisition of  InferMed , ... technology company. InferMed,s Arezzo technology supports clinicians in ...
(Date:6/30/2015)... ... ... Students and faculty from Beijing City University will arrive ... an applied biotechnology course team-taught by faculty members from both institutions. The result ... universities and is taught on both continents. , “Our alliance with Beijing City ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  Today, Americord ... the U.S., announced Andrew Horne , a partner at ... Advisory Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... appointment to Americord,s Advisory Board," says Martin Smithmyer , ... experience in his legal career that will assist Americord,s growth ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... pulmonary nicotine delivery device to help people quit smokingJEFFERSON, N.C., ... Next Safety, Inc. (NSI) as chairman. In his smoking cessation ... times, as well as the CBS Evening News with Dan ... a B.S. in Psychology, an M.S. in Clinical Psychology and ...
... Technology also has potential to fight cancer, rheumatoid ... vaccinesVIENNA, Va., April 27 CEL-SCI Corporation (NYSE ... presentation of data at the 11th annual National ... demonstrates how vaccines utilizing its L.E.A.P.S.(TM) (Ligand Epitope ...
... Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ) announced ... product candidate, Acetavance(TM) (intravenous acetaminophen), will be presented at ... (ASRA) 34th Annual Regional Anesthesia Meeting in Phoenix, Arizona ... Hospital Medicine (SHM) Annual Meeting in Chicago, Illinois on ...
Cached Biology Technology:Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman 2CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 2CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 3CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 4Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences 2
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, a ... authentication solutions, today announced enhanced functionality of its ... solution.  The enhancements build on the native ... DigitalPersona Altus platform and provide expanded mobile ... In today,s environment of increasing cyber-attacks ...
(Date:6/17/2015)... , June 17, 2015  Synaptics Inc. ... interface solutions, today announced that Xiaomi, one of ... Synaptics ® ClearPad ® family of ... driver integrated circuits (DDICs) for its latest smartphones, ... leveraging ClearPad for full in-cell display solutions and ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... quality trends in forested streams across the country that are ... The study, which draws on decades, worth of data from ... the value of long-term data in understanding the patterns and ... is published in the current issue of the journal ...
... when DNA sequence data is growing exponentially", says Miami ... of the genes that we identify, we have no ... in a foreign language, waiting to be deciphered." Understanding ... emerged at the forefront of molecular biology. Many groups ...
... the differing fates of individual T cells, researchers have ... response can be effectively modeled. The crucial question: What ... will mobilize to fight an acute infection and which ... basis of the immunological memory? The scientists, findings, published ...
Cached Biology News:Study explores long-term water quality trends in near-pristine streams 2Genomic data are growing, but what do we really know? 2Insights into the immune system, from the fates of individual T cells 2Insights into the immune system, from the fates of individual T cells 3
...
...
Contains L-glutamine....
... High Resolution - Efficiently ... 50 to 1000 bp. ... sizing PCR fragments, small ... restriction enzyme digestion, and ...
Biology Products: